The prevalence is forecasted to be growing at a CAGR of 2.61% and 1.61% respectively for the U.S. and the U.K for the period 2022-2032
BIS Research, the global leader in providing market intelligence on deep technologies, has released its latest study titled Extensive Stage Small Cell Lung Cancer Market – A Global and Regional Analysis.
The prevalence of extensive stage small lung cancer is estimated to increase in five of the seven major markets included in the study. Geographically, the U.S. remains at the top with an estimated prevalence for 2021 of more than 47,000 patients followed by the U.K. with over 8,500 patients.
The following factors are responsible for the increase in the market prevalence of extensive stage small cell lung cancer:
- Potential therapeutic effects of immune checkpoint inhibitors in improving overall survival among cancer patients
- Treatment directed toward decreasing the chemotherapy-induced toxic effects
The detailed study is a compilation of 31 market data tables and 60 figures spread through 153 pages.
Check out the detailed table of content here:
https://bisresearch.com/requestsample?id=1407&type=toc
Analyst’s Take on the Market Projection
According to Tausif Qudsi, Principal Analyst, BIS Research, “global extensive stage small cell lung cancer market is extremely challenging along with existing opportunities. With positive therapeutic benefits demonstrated by immune checkpoint inhibitors and approval of Cosela (Trilaciclib) to decrease the chemotherapeutic-induced toxic effects of myelosuppression, the market appears positive. The dominance of immune checkpoint inhibitors in the pipeline highlights the potential of the global extensive stage small cell lung cancer market.”
Request a FREE sample of this report here:
https://bisresearch.com/requestsample?id=1407&type=download
Existing Competitive Landscape
The current global extensive-stage small cell lung cancer market has two approved immune checkpoint inhibitors namely Imfinzi (Durvalumab) from AstraZeneca PLC and Tecentriq (Atezolizumab) from F. Hoffmann La-Roche Ltd. Zepzelca (Lurbinectedine) from Jazz Pharmaceuticals Plc and Cosela (Trilaciclib) from G1 Therapeutics Inc. are other two products approved for the treatment of extensive stage small cell lung cancer patients. Currently, there are four products available in the market which are patented. The chemotherapeutic products which constituted the standard of care have all become generic. There is a rich clinical pipeline of extensive stage small cell lung cancer market with the dominance of immune checkpoint inhibitors along with bispecific antibodies.
Want to learn more about the latest trends in healthcare? Speak to our analysts
Exclusive DeepTech™ MAP Analysis for Healthcare by BIS Research:
Lung Cancer Genomic Testing Market
About BIS Research:
BIS Research is a global B2B market intelligence and advisory firm focusing on deep technology and related emerging trends which can disrupt the market dynamics in the near future. We publish more than 200 market intelligence studies annually that focus on several deep technology verticals.
Our strategic market analysis emphasizes on market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.
BIS Research offers syndicate as well as custom studies and expert consultations to firms, providing them with specific and actionable insights on novel technology markets, business models, and competitive landscapes.
Contact:
Bhavya Banga
Email: [email protected]
BIS Research Inc.
39111 PASEO PADRE PKWY STE 313,
FREMONT CA 94538-1686
Visit our Blog @ https://bisresearch.com/news
Get Expert Insights @ https://community.insightmonk.com
Connect with us on LinkedIn @ https://www.linkedin.com/company/bis-research
Connect with us on Twitter@ https://twitter.com/BISResearch
Contact Information:
Tags:
Reportedtimes, Extended Distribution, iCN Internal Distribution, Research Newswire, English